Document Detail


Clinical perspectives on the role of anti-platelet and statin therapy in patients with vascular diseases.
MedLine Citation:
PMID:  15320479     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis and is associated with a several-fold increased risk of cardiovascular morbidity and mortality. Statins and anti-platelet therapy have been unequivocally shown to be beneficial in patients with coronary artery disease, but minimal data exist on the effectiveness of these agents in patients with PAD and those undergoing peripheral vascular interventions. One recent study has demonstrated that statins are very effective as secondary preventive measures in patients with PAD but continue to be underutilized in this cohort. In our institutional peripheral interventional database, after adjustment for demographics and comorbidities, statin therapy (OR=0.21, 95% CI 0.05-0.86, p=0.03) and clopidogrel therapy (OR=0.17, 95% CI 0.04-0.78, p=0.02) were both associated with a significant reduction of the composite event rate of death, myocardial infarction and stroke at 6 months. In this article, we critically review the existing literature on the role of anti-platelet and statin therapy in reducing cardiovascular events in patients with PAD. Appropriate use of these agents may significantly decrease the cardiovascular morbidity and mortality of patients with PAD.
Authors:
Sujoya Dey; Debabrata Mukherjee
Related Documents :
19375269 - Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases.
24217829 - A less aggressive therapeutic option for electrical storm.
9329379 - Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation.
15172899 - Association of statin therapy with outcomes of acute coronary syndromes: the grace study.
18767409 - Prevalence and particularities of dyslipidaemia in subjects with coronary heart disease.
15680709 - Statins decrease perioperative cardiac complications in patients undergoing noncardiac ...
21700089 - Monomorphic ventricular tachycardia and mediastinal adenopathy due to granulomatous inf...
1554279 - Beyond cold cardioplegia.
11214429 - Cardiovascular diseases and nitric oxide in humans.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current vascular pharmacology     Volume:  1     ISSN:  1570-1611     ISO Abbreviation:  Curr Vasc Pharmacol     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2004-08-23     Completed Date:  2004-12-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101157208     Medline TA:  Curr Vasc Pharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  329-33     Citation Subset:  IM    
Affiliation:
Division of Cardiology, University of Michigan, Ann Arbor, Michigan 48109-0311, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Arteriosclerosis / physiopathology,  prevention & control*
Clinical Trials as Topic
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*,  therapeutic use
Peripheral Vascular Diseases / physiopathology,  prevention & control*
Platelet Aggregation Inhibitors / pharmacology*,  therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Platelet Aggregation Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vasomotor effects of iodinated contrast media: just side effects?
Next Document:  Cardiovascular diseases and the nitric oxide pathway.